The few available trials designed with weight loss as the principal endpoint and enrolling nondiabetic patients with obesity have shown that GLP-1 receptor agonists have a potential use as drugs for the treatment of overweight [14, 15]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.